ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

Showing results for Cancer Drugs

February 15, 2019

President Trump signed into law a funding bill that provides FDA with $3.08 billion in government funding for fiscal year 2019 – a $269 million increase, and the largest boost to FDA in at least five years.

February 7, 2019

On February 15 from 11:00 AM - 12:00 PM ET, ASCO will host a webinar discussing current standards for the safe handling of hazardous drugs. The webinar will look at existing safe handling standards from the United States Pharmacopeia (USP) and the National Institute for Occupational Safety and Health (NIOSH), and provide an overview of ASCO’s recently released standards.

February 6, 2019

On February 6, 2019, the Food and Drug Administration approved caplacizumab-yhdp (CABLIVI®, Ablynx NV) for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

February 5, 2019

In a comment letter to the Centers for Medicare & Medicaid Services (CMS), ASCO urged the agency to protect patient access to necessary cancer care under Medicare Advantage (MA) and Medicare Part D. The comments were submitted in response to proposed changes to MA and Part D aimed at lowering drug prices.

January 15, 2019

On January 14, 2019, the Food and Drug Administration approved cabozantinib (CABOMETYX®, Exelixis, Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

January 8, 2019

The American Society of Clinical Oncology (ASCO) today published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology. ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is needed to identify evidence-based safety measures.

January 2, 2019

As part of the Trump Administration’s continuing effort to address the cost of prescription drugs, the Centers for Medicare & Medicaid Services (CMS) recently solicited input on a proposed new pilot program to test mechanisms for reducing drug costs. The International Pricing Index Model (IPI) for Medicare Part B drugs proposes sweeping reforms that would, in part, benchmark some Medicare Part B drug prices against other countries and change how providers get paid for administering drugs to patients.